Journal
NATURE COMMUNICATIONS
Volume 11, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-020-17703-6
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [DFG-FOR2886 PANDORA, CRC1181]
- Bundesministerium fur Bildung und Forschung (BMBF)
- 4D-Nanoscope ERC Synergy Project [810316]
- IMI
- Stiftung gemeinnutzige Gesellschaft mbH
- Else Kroner-Fresenius-Stiftung (Else Kroner-Memorial-Stipendium) [2019_EKMS.27]
- Emerging Fields Initiative MIRACLE of the Friedrich-Alexander-Universitat Erlangen-Nurnberg
- European Research Council (ERC) [810316] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available